DocGo 경영진
경영진 기준 점검 2/4
DocGo CEO는 Lee Bienstock, Sep2023 에 임명되었습니다 의 임기는 2.67 년입니다. 총 연간 보상은 $3.57M, 22% 급여 및 78% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $379.54K 가치에 해당하는 회사 주식의 0.68% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 3.4 년과 2 년입니다.
핵심 정보
Lee Bienstock
최고경영자
US$3.6m
총 보수
| CEO 급여 비율 | 21.98% |
| CEO 재임 기간 | 2.7yrs |
| CEO 지분 보유율 | 0.7% |
| 경영진 평균 재임 기간 | 3.4yrs |
| 이사회 평균 재임 기간 | 2yrs |
최근 경영진 업데이트
Recent updates
분석 기사 • May 14
US$1.87: That's What Analysts Think DocGo Inc. (NASDAQ:DCGO) Is Worth After Its Latest Results
DocGo Inc. ( NASDAQ:DCGO ) shareholders are probably feeling a little disappointed, since its shares fell 5.5% to...
내러티브 업데이트 • May 14
DCGO: Transport EBITDA And 2026 Guidance Will Support Future Upside Potential
Narrative Update The consensus analyst price target for DocGo has been reduced toward the mid single digit range, with cuts such as the move from $4.00 to $2.50. Analysts are factoring in mixed Q4 results, modestly higher 2026 transport guidance, updated fair value estimates near $1.87, a slightly higher discount rate of about 7.3%, revised revenue growth assumptions around 4.2%, a profit margin assumption near 6.1%, and a lower future P/E closer to 10.8x.
내러티브 업데이트 • Apr 23
DCGO: Transport EBITDA Outlook Will Drive Future Upside Potential
Analysts recently trimmed their DocGo price targets, with cuts such as Stifel's move from $4.00 to $2.50, citing mixed Q4 results, modestly higher 2026 transport guidance, and updated expectations for growth, margins, and P/E assumptions. Analyst Commentary Bullish analysts acknowledge the recent price target cuts but still point to several areas they see as supportive for DocGo's valuation and long term execution story.내러티브 업데이트 • Apr 07
DCGO: Transport EBITDA And 2026 Guidance Will Drive Future Upside Potential
Narrative Update Analysts have nudged their price expectations for DocGo lower, trimming aggregate targets by around $0.10 as they factor in mixed Q4 results, modestly higher 2026 transport guidance, and updated views on margins, growth, and future P/E multiples. Analyst Commentary Recent Street commentary on DocGo is mixed, with some analysts focusing on potential value in the transport segment and others reacting to lower price targets and Q4 variability.내러티브 업데이트 • Mar 24
DCGO: Transport EBITDA Outlook Will Support Future Upside Potential
Narrative Update The analyst price target for DocGo has been reduced from $4.00 to $2.50, as analysts factor in mixed Q4 results while crediting modestly higher 2026 transport guidance and the view that the transport unit alone could potentially support proceeds above the current share price. Analyst Commentary Recent research reflects a more cautious stance on DocGo, with the price target reduced to US$2.50 while still crediting specific strengths in the transport segment.
내러티브 업데이트 • Mar 10
DCGO: Future Returns Will Rely On Expanding Telehealth Weight Loss Services
Analysts have trimmed their price targets on DocGo to reflect slightly softer revenue growth assumptions, along with somewhat stronger profit margin and future P/E expectations, resulting in only a modest adjustment to their overall valuation view. What's in the News Nasdaq notified DocGo on January 26, 2026 that the company is not in compliance with the $1.00 minimum bid price requirement.내러티브 업데이트 • Feb 22
DCGO: Buyback Extension And Telehealth Expansion Will Support Future Upside
Analysts have trimmed their price targets on DocGo to $2.50, citing slightly higher discount rate assumptions, a modestly softer profit margin outlook, and a higher future P/E multiple as key drivers of the revised view. What's in the News Nasdaq notified DocGo on January 26, 2026 that the company is not in compliance with the minimum US$1.00 bid price requirement, triggering a 180 day window until July 27, 2026 to regain compliance before potential further action is considered (Delistings).내러티브 업데이트 • Feb 08
DCGO: Future Returns Will Rely On Expanding Longitudinal Virtual Weight Loss Care
Analysts have slightly reduced their price target on DocGo, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. This adjustment signals a more cautious stance on the company’s risk and earnings profile.내러티브 업데이트 • Jan 24
DCGO: Buyback Extension And M&A Pipeline Will Support Future Upside
Analysts have trimmed their price target on DocGo to reflect a fair value shift from about $3.08 to roughly $2.50. The change reflects updated assumptions around revenue contraction, slightly higher required returns, modestly better profit margins, and a lower future P/E multiple.내러티브 업데이트 • Jan 10
DCGO: Future Returns Will Depend On Expanding Longitudinal Care Partnerships
Analysts have made a small upward tweak to their price target on DocGo, reflecting slightly more constructive assumptions around revenue growth and long term profit margins, while keeping the projected P/E and discount rate almost unchanged. What's in the News Robbins Geller Rudman & Dowd LLP announced a proposed US$12.5 million cash settlement in the DocGo securities class action, subject to court approval at a hearing scheduled for March 24, 2026 in the Southern District of New York (Lawsuits & Legal Issues).내러티브 업데이트 • Dec 26
DCGO: Future Returns Will Depend On Longitudinal Care And Maturing Revenue Mix
Analysts have nudged up their price target on DocGo by a modest amount, citing slightly higher long term profit margin expectations and a marginally richer future earnings multiple. Together, these factors support a small increase in estimated fair value.내러티브 업데이트 • Dec 12
DCGO: Future Returns Will Depend On New Longitudinal Care Contracts
Analysts have lowered their price target on DocGo from approximately 1.60 dollars to 1.00 dollars, citing a higher required discount rate and a reduced valuation multiple, despite modest improvements in the projected revenue trajectory and profit margins. What's in the News DocGo signaled an active mergers and acquisitions strategy, highlighting its ability to acquire traditional health care assets and layer on its technology and mobile health capabilities to support long-term growth and shareholder value (company commentary) The company provided updated guidance, forecasting 2025 revenue of 315 million to 320 million dollars, including 68 million to 70 million dollars from migrant-related contracts, and 2026 revenue of 280 million to 300 million dollars with no migrant-related revenue (corporate guidance) DocGo recorded a goodwill impairment charge of approximately 8.7 million dollars in the third quarter of 2025, reflecting a write-down of acquired assets (company filing) DocGo announced a new Longitudinal Care Services program with a California-based insurer, targeting 10,000 under-engaged members with combined telehealth and in-home clinical services starting in the fourth quarter (client announcement) The company is expanding its partnership with a national insurer in New Mexico, launching care gap closure and planned primary care services for 10,000 Turquoise Care members through at-home visits and chronic care support (client announcement) Valuation Changes The fair value estimate has fallen significantly from approximately $1.60 to $1.00 per share.분석 기사 • Sep 26
Benign Growth For DocGo Inc. (NASDAQ:DCGO) Underpins Its Share Price
When close to half the companies operating in the Healthcare industry in the United States have price-to-sales ratios...분석 기사 • May 16
DocGo Inc. (NASDAQ:DCGO) Looks Inexpensive After Falling 38% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the DocGo Inc. ( NASDAQ:DCGO ) share price has dived 38% in the last thirty days...분석 기사 • Apr 16
Is It Too Late To Consider Buying DocGo Inc. (NASDAQ:DCGO)?
DocGo Inc. ( NASDAQ:DCGO ), might not be a large cap stock, but it saw significant share price movement during recent...분석 기사 • Mar 06
We Like The Quality Of DocGo's (NASDAQ:DCGO) Earnings
Despite posting healthy earnings, DocGo Inc.'s ( NASDAQ:DCGO ) stock has been quite weak. We have done some analysis...분석 기사 • Mar 01
These 4 Measures Indicate That DocGo (NASDAQ:DCGO) Is Using Debt Safely
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Feb 11
Subdued Growth No Barrier To DocGo Inc. (NASDAQ:DCGO) With Shares Advancing 33%
DocGo Inc. ( NASDAQ:DCGO ) shareholders have had their patience rewarded with a 33% share price jump in the last month...
새로운 내러티브 • Sep 24
Innovative Health Initiatives Promise Growth Amid Analysts' Concerns Over Future Earnings And Margins
Strategic partnerships with virtual-only providers and operational efficiency improvements indicate a comprehensive approach to expanding health solutions and improving margins.분석 기사 • Aug 05
DocGo Inc. (NASDAQ:DCGO) Doing What It Can To Lift Shares
DocGo Inc.'s ( NASDAQ:DCGO ) price-to-earnings (or "P/E") ratio of 15.3x might make it look like a buy right now...분석 기사 • Jul 17
At US$3.40, Is DocGo Inc. (NASDAQ:DCGO) Worth Looking At Closely?
DocGo Inc. ( NASDAQ:DCGO ), might not be a large cap stock, but it saw a decent share price growth of 20% on the...분석 기사 • Jun 11
These 4 Measures Indicate That DocGo (NASDAQ:DCGO) Is Using Debt Safely
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Seeking Alpha • Mar 20
DocGo: Upside Remains Attractive After Share Price Decline
Summary DocGo stock receives a buy rating due to attractive upside potential and commendable execution demonstrated by management. Recent results show strong revenue growth and margin expansion, driven by steady contracts and growth in trip volumes and average price. Management's positive commentary, impressive pipeline, and plans for RFP submissions in FY24 indicate continued momentum and cross-sell success. Read the full article on Seeking Alpha분석 기사 • Feb 13
Does DocGo (NASDAQ:DCGO) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Feb 05
DocGo: Good Performance, Trust Issues
Summary DocGo has recently faced a series of negative events, including criticism from the NY Times, Comptroller contract rejection, CEO departure on false CV allegations, and a short report. Despite these challenges, the company presented strong Q3 2023 results, positively revised FY 2023 guidance, addressed the short report, announced new partnerships and a share repurchase program. Investors must decide if they should trust DocGo's performance and financials or let the dust settle first. Read the full article on Seeking Alpha분석 기사 • Jan 25
Why DocGo Inc. (NASDAQ:DCGO) Could Be Worth Watching
DocGo Inc. ( NASDAQ:DCGO ), might not be a large cap stock, but it led the NASDAQCM gainers with a relatively large...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$188m |
| Dec 31 2025 | US$4m | US$785k | -US$182m |
| Sep 30 2025 | n/a | n/a | -US$52m |
| Jun 30 2025 | n/a | n/a | -US$18m |
| Mar 31 2025 | n/a | n/a | -US$641k |
| Dec 31 2024 | US$8m | US$785k | US$20m |
| Sep 30 2024 | n/a | n/a | US$31m |
| Jun 30 2024 | n/a | n/a | US$30m |
| Mar 31 2024 | n/a | n/a | US$22m |
| Dec 31 2023 | US$11m | US$582k | US$7m |
| Sep 30 2023 | n/a | n/a | US$7m |
| Jun 30 2023 | n/a | n/a | US$6m |
| Mar 31 2023 | n/a | n/a | US$20m |
| Dec 31 2022 | US$4m | US$415k | US$35m |
보상 대 시장: Lee의 총 보수(USD3.57M)는 US 시장에서 비슷한 규모 기업의 평균(USD649.34K)보다 높습니다.
보상과 수익: Lee의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Lee Bienstock (40 yo)
2.7yrs
재임 기간
US$3,571,951
보수
Mr. Lee Bienstock served as President at DocGo Inc. since December 31, 2022 until September 15, 2023. He served as Chief Operating Officer at DocGo Inc. since March 2022 until September 15, 2023 and serves...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Director | 2.7yrs | US$3.57m | 0.68% $ 379.5k | |
| Treasurer & CFO | 3.4yrs | US$1.70m | 0.35% $ 194.2k | |
| General Counsel | 4.5yrs | US$1.32m | 0.094% $ 52.4k | |
| Chief Information Officer | 1.7yrs | 데이터 없음 | 데이터 없음 | |
| Vice President of Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Chief Compliance Officer | 4.2yrs | US$1.84m | 0.15% $ 83.7k | |
| Vice President of Human Resources | no data | 데이터 없음 | 데이터 없음 | |
| CEO of Clinical Practice Group & Member of Medical Advisory Board | no data | 데이터 없음 | 데이터 없음 |
3.4yrs
평균 재임 기간
53.5yo
평균 나이
경험이 풍부한 관리: DCGO의 경영진은 경험이 있음으로 간주됩니다(평균 재임 3.4 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Director | 2.1yrs | US$3.57m | 0.68% $ 379.5k | |
| General Counsel | 4.5yrs | US$1.32m | 0.094% $ 52.4k | |
| CEO of Clinical Practice Group & Member of Medical Advisory Board | 1.9yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 4.5yrs | US$225.50k | 0.61% $ 343.7k | |
| Independent Director | 4.5yrs | US$193.00k | 0.45% $ 253.3k | |
| Member of Medical Advisory Board | 1.9yrs | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Chairman | 1.6yrs | US$400.00k | 0.015% $ 8.5k | |
| Member of Medical Advisory Board | 1.9yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 3.5yrs | US$208.00k | 0.017% $ 9.3k | |
| Independent Director | 4.5yrs | US$234.25k | 0.057% $ 31.8k | |
| Chairman of Medical Advisory Board | 1.9yrs | 데이터 없음 | 데이터 없음 | |
| Member of Medical Advisory Board | 1.9yrs | 데이터 없음 | 데이터 없음 |
2.0yrs
평균 재임 기간
66yo
평균 나이
경험이 풍부한 이사회: DCGO의 이사회는 경험이 부족한 것으로 간주됩니다(평균 재임 2 년) — 신규 이사회일 가능성이 있습니다.
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/20 20:35 |
| 종가 | 2026/05/20 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
DocGo Inc.는 7명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Sarah James | Barclays |
| David Larsen | BTIG |
| Richard Close | Canaccord Genuity |